120 related articles for article (PubMed ID: 8949993)
61. Testicular germ cell tumours: the paradigm of chemo-sensitive solid tumours.
di Pietro A; Vries EG; Gietema JA; Spierings DC; de Jong S
Int J Biochem Cell Biol; 2005 Dec; 37(12):2437-56. PubMed ID: 16099193
[TBL] [Abstract][Full Text] [Related]
62. Survival of patients with viable malignant non-seminomatous germ cell tumour persistent after cisplatin-based induction chemotherapy.
Hollender A; Stenwig EA; Ous S; Fosså SD
Eur Urol; 1997; 31(2):141-7. PubMed ID: 9076455
[TBL] [Abstract][Full Text] [Related]
63. Immunocytochemical analysis of apoptotic bone marrow cells after treatment of mice with WR-2721 and chemotherapeutic drugs.
Mazur L; Czyzewska A
Folia Histochem Cytobiol; 2001; 39(2):63-6. PubMed ID: 11374841
[TBL] [Abstract][Full Text] [Related]
64. Influence of amifostine on reconstitution of lymphocyte subpopulations after conventional- and high-dose chemotherapy in patients with germ cell tumor.
Rick O; Beyer J; Schwella N; Siegert W
Ann Hematol; 2002 Dec; 81(12):717-22. PubMed ID: 12483368
[TBL] [Abstract][Full Text] [Related]
65. Improvement of the in vitro safety profile and cytoprotective efficacy of amifostine against chemotherapy by PEGylation strategy.
Yang X; Ding Y; Ji T; Zhao X; Wang H; Zhao X; Zhao R; Wei J; Qi S; Nie G
Biochem Pharmacol; 2016 May; 108():11-21. PubMed ID: 26944193
[TBL] [Abstract][Full Text] [Related]
66. Two cycles of cisplatin-based chemotherapy for low-volume retroperitoneal stage II nonseminomatous germ cell tumours.
Steiner H; Müller T; Gozzi C; Akkad T; Bartsch G; Berger AP
BJU Int; 2006 Aug; 98(2):349-52. PubMed ID: 16626306
[TBL] [Abstract][Full Text] [Related]
67. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
Culy CR; Spencer CM
Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
[TBL] [Abstract][Full Text] [Related]
68. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
Kemp G; Rose P; Lurain J; Berman M; Manetta A; Roullet B; Homesley H; Belpomme D; Glick J
J Clin Oncol; 1996 Jul; 14(7):2101-12. PubMed ID: 8683243
[TBL] [Abstract][Full Text] [Related]
69. High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer.
Schiller JH
Semin Oncol; 1996 Aug; 23(4 Suppl 8):78-82. PubMed ID: 8783672
[TBL] [Abstract][Full Text] [Related]
70. Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts.
Abraham D; Abri S; Hofmann M; Höltl W; Aharinejad S
J Urol; 2003 Oct; 170(4 Pt 1):1388-93. PubMed ID: 14501775
[TBL] [Abstract][Full Text] [Related]
71. Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
Korst AE; Boven E; van der Sterre ML; Fichtinger-Schepman AM; van der Vijgh WJ
Br J Cancer; 1997; 75(10):1439-46. PubMed ID: 9166935
[TBL] [Abstract][Full Text] [Related]
72. 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model.
Schobert R; Biersack B; Dietrich A; Effenberger K; Knauer S; Mueller T
J Med Chem; 2010 Sep; 53(18):6595-602. PubMed ID: 20731355
[TBL] [Abstract][Full Text] [Related]
73. Fertility after chemotherapy for testicular germ cell cancer.
Pont J; Albrecht W
Fertil Steril; 1997 Jul; 68(1):1-5. PubMed ID: 9207575
[TBL] [Abstract][Full Text] [Related]
74. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.
Mueller T; Voigt W; Simon H; Fruehauf A; Bulankin A; Grothey A; Schmoll HJ
Cancer Res; 2003 Jan; 63(2):513-21. PubMed ID: 12543810
[TBL] [Abstract][Full Text] [Related]
75. [Management of non-seminomatous germ cell tumors of the testes].
Kawai K; Akaza H
Gan To Kagaku Ryoho; 2000 Apr; 27(4):522-9. PubMed ID: 10790993
[TBL] [Abstract][Full Text] [Related]
76. Cisplatin-induced in vivo differentiation of human embryonal carcinoma.
Mizutani Y; Sato N; Kawauchi A; Nonomura N; Fukushima M; Miki T
BJU Int; 2002 Mar; 89(4):454-8. PubMed ID: 11872042
[TBL] [Abstract][Full Text] [Related]
77. Paclitaxel in salvage therapy for germ cell tumors.
Motzer RJ
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-83-S15-85. PubMed ID: 9346229
[TBL] [Abstract][Full Text] [Related]
78. In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR1065.
Verstappen CC; Geldof AA; Postma TJ; Heimans JJ
J Neurooncol; 1999 Aug; 44(1):1-5. PubMed ID: 10582662
[TBL] [Abstract][Full Text] [Related]
79. Protective effects of amifostine, curcumin and caffeic acid phenethyl ester against cisplatin-induced testis tissue damage in rats.
Mercantepe T; Unal D; Tümkaya L; Yazici ZA
Exp Ther Med; 2018 Apr; 15(4):3404-3412. PubMed ID: 29545862
[TBL] [Abstract][Full Text] [Related]
80. Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts.
Treskes M; Nijtmans L; Fichtinger-Schepman AM; van der Vijgh WJ
Anticancer Res; 1992; 12(6B):2261-5. PubMed ID: 1338281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
